Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Ralf Reilmann(George Huntington Institute), Hope Heller(Georgetown University), Douglas R. Langbehn(University of Iowa Hospitals and Clinics), Stephanie Gallehawk, Ferdinando Squitieri(University of British Columbia), Allison Coleman(University of British Columbia), Stefan Bohlen, Phyllis Chua, Nicholas J. Gross(St. Francis Hospital), Juha‐Matti Savola(Teva Pharmaceuticals (Switzerland)), Karl Kieburtz(University of Rochester), Kevin Biglan(Georgetown University), Carey Gonzales, Rebecca Cousins, Anna Teige Wickenberg(Teva Pharmaceuticals (Israel)), Spyros Papapetropoulos(Massachusetts General Hospital), Beth Borowsky(Teva Pharmaceuticals (United States)), Michael R. Hayden(Family Research Institute), Giuseppe De Michele(University of Naples Federico II), Markus Beuth, Anne‐Catherine Bachoud‐Lévi, Igor D. Grachev(Teva Pharmaceuticals (United States)), Andrew McGarry(Cooper Medical School of Rowan University), G. Bernhard Landwehrmeyer, J.P. Azulay, Fabienne Calvas, Eli Eyal(Teva Pharmaceuticals (Israel)), Roger A. Barker(University of Cambridge), Raphael M. Bonelli, Pinky Agarwal, Jill Davison, Andrew Feigin(Georgetown University), Karen E. Anderson(Georgetown University), Robin Schubert(George Huntington Institute), Stéphanie Blin, Agnieszka Bebak, Simona Castagliuolo, Laura Dornhege, Beatrix Heim, David Craufurd, Terrence Chong, Jane Griffith, Sue Caldwell, Jonielyn Carlos, Mark Guttman(Georgetown University), А.В. Густов, Pascale Gauteul, E Decorte, Jody Corey‐Bloom
Cited by 108
Related Papers
Huntington disease
|Nature Reviews Disease Primers|2015|1.6k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976